SLC5A2 and heart failure: In patients with established atherosclerotic cardiovascular disease (or those at elevated risk), or chronic kidney disease or heart failure, SGLT2-inhibitors are the recommended drugs in international guidelines, and GLP1-RAs are recommended for those with atherosclerotic cardiovascular disease26.